Citadel Advisors
SXTP icon

Citadel Advisors’s 60 Degrees Pharmaceuticals SXTP Stock Holding History

Citadel Advisors’s Portfolio SXTP Stock Details SXTP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-505
Closed -$12.7K – 15370
2024
Q3 		$12.7K Buy
+505
New +$18.7K ﹤0.01% 13091
2024
Q2 		– Sell
-419
Closed -$26.3K – 15366
2024
Q1 		$26.3K Buy
+419
New +$46.7K ﹤0.01% 12814
2023
Q4 		– Sell
-92
Closed -$16.4K – 15234
2023
Q3 		$16.4K Buy
+92
New +$38.2K ﹤0.01% 12779

Other funds holding SXTP

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
SHF
Safe Harbor Fiduciary Pensacola, Florida $105M AUM
BWL
Bogart Wealth LLC Mclean, Virginia $2.6B AUM 18.62% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Citadel Advisors's SXTP Position: Q4 2024 in Review

Citadel Advisors sold out of 60 Degrees Pharmaceuticals (SXTP) in Q4 2024, closing a stake of 505 shares — an estimated $12.7K sold.

Citadel Advisors first reported a position in SXTP in Q3 2023 and held it in 3 quarters. The position peaked at $26.3K in Q1 2024. 9 funds tracked by Wall St. Rank hold SXTP as of Q4 2024.

  • Citadel Advisors reported no remaining 60 Degrees Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Citadel Advisors sold 505 60 Degrees Pharmaceuticals shares in Q4 2024, an estimated $12.7K.
  • Citadel Advisors first reported a position in 60 Degrees Pharmaceuticals in Q3 2023 and held it in 3 quarters.
  • Citadel Advisors's 60 Degrees Pharmaceuticals position peaked at $26.3K in Q1 2024.
  • 9 funds tracked by Wall St. Rank held 60 Degrees Pharmaceuticals as of Q4 2024.

Based on Citadel Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.